Medicine and Dentistry
Breast Cancer
100%
Malignant Neoplasm
90%
Radiation Therapy
81%
Neoplasm
79%
Overall Survival
58%
Disease
52%
Quality of Life
43%
Recurrent Disease
37%
Symptom
35%
Cohort Analysis
35%
Hazard Ratio
31%
Progression Free Survival
31%
Patient-Reported Outcome
30%
Randomized Controlled Trial
27%
Systematic Review
26%
Ovarian Cancer
25%
Cancer Therapy
25%
Head and Neck Cancer
25%
Prostate Cancer
24%
Neuroendocrine Tumor
22%
Clinical Trial
21%
Adverse Event
21%
Glioblastoma
20%
Symptomatic Treatment
20%
Lung Cancer
19%
Arm
19%
Meta-Analysis
18%
Placebo
18%
Positron Emission Tomography-Computed Tomography
17%
Testis Cancer
17%
Biological Marker
16%
Diagnosis
16%
Metastatic Carcinoma
16%
Oncology
16%
Positron Emission Tomography
16%
Ganglioglioma
16%
Non Small Cell Lung Cancer
16%
Positron Emission Tomography
16%
Pediatrics
13%
Prognostic Factor
13%
Immunotherapy
12%
Hodgkin's Lymphoma
12%
Niraparib
12%
Primary Tumor
11%
Proportional Hazards Model
11%
Magnetic Resonance Imaging
11%
Adjuvant Therapy
11%
Colorectal Cancer
11%
Oropharynx Squamous Cell Carcinoma
11%
Adjuvant Chemotherapy
10%
Fluorodeoxyglucose F 18
10%
Seminoma
10%
Survival Rate
10%
Surgery
10%
Recurrent Ovarian Cancer
10%
Solid Malignant Neoplasm
10%
Proton Therapy
10%
Clinician
10%
Prevalence
10%
Maintenance Therapy
10%
Opiate
9%
Bladder Cancer
9%
Head and Neck Squamous Cell Carcinoma
9%
Receptor
9%
Germ Cell Cancer
9%
Targeted Therapy
9%
Bevacizumab
9%
Estrogen Receptor
8%
Side Effect
8%
Fluorine-18
8%
Cancer Diagnosis
8%
P16
8%
Computer Assisted Tomography
8%
Adenocarcinoma
8%
Chemoradiotherapy
8%
Trastuzumab
8%
Positron Emission Tomography - Magnetic Resonance Imaging
8%
Metastatic Breast Cancer
7%
PARP Inhibitor
7%
Phosphotransferase
7%
Odds Ratio
7%
Endometrial Cancer
7%
BRCA1
7%
Cervical Cancer
7%
Stereotactic Body Radiation Therapy
7%
Recurrence Free Survival
7%
Hormone Therapy
7%
Clinical Stage
7%
Wart Virus
7%
Drug Megadose
6%
Brain Tumor
6%
Squamous Cell Carcinoma
6%
Germinoma
6%
BRCA2
6%
Radiation Therapy Planning
6%
Female Genital Tract Cancer
6%
Disease Free Survival
6%
Oropharyngeal Cancer
6%
Castration Resistant Prostate Cancer
6%
Larotrectinib
6%
Keyphrases
Denmark
56%
Overall Survival
55%
Breast Cancer
53%
Confidence Interval
49%
Radiotherapy
44%
Chemotherapy
44%
Hazard Ratio
37%
Tumor
37%
Cancer Patients
35%
Progression-free Survival
32%
Randomized Controlled Trial
31%
Quality of Life
30%
Head-and-neck Cancer
27%
Patient-reported Outcomes
27%
Meta-analysis
24%
Radiation Therapy
21%
ENGOT
21%
National Cohort Study
21%
Early Breast Cancer
21%
Breast Cancer Patients
21%
Health-related Quality of Life
19%
Glioblastoma
18%
Cancer Treatment
18%
Clinical Trials
18%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
17%
Prostate Cancer
17%
Placebo
16%
Randomized Trial
15%
Systematic Meta-analysis
15%
In Cancer
15%
Glioma
14%
Phase II Trial
14%
Non-small Cell Lung Cancer (NSCLC)
13%
Older Adults
13%
Phase II Study
13%
Copenhagen
13%
High Risk
13%
Adverse Events
13%
Positron Emission Tomography-computed Tomography (PET-CT)
12%
Niraparib
12%
Lung Cancer
12%
Solid Tumors
12%
Prognostic Factors
12%
Adjuvant Chemotherapy
12%
Patients with Cancer
11%
Breast Cancer Recurrence
11%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
11%
Adjuvant Therapy
11%
Testicular Cancer
11%
Ovarian Cancer
11%
Neuroendocrine Neoplasms
11%
Palliative Care
11%
Germ Cell Tumor
10%
Colorectal Cancer
10%
Human Epidermal Growth Factor Receptor 2 (HER2)
10%
Primary Palliative Care
10%
Postmenopausal Women
10%
Positron Emission Tomography
10%
Bladder Cancer
10%
Oncology
10%
Odds Ratio
10%
Trastuzumab
10%
Prognostic Value
10%
Adult Cancer
10%
Healthcare Professionals
9%
Comorbidity
9%
PARP Inhibitor (PARPi)
9%
Metastatic Breast Cancer
9%
Risk Factors
9%
Population-based Study
9%
Median Overall Survival
9%
Bevacizumab
9%
Oncological Treatment
9%
PET-MRI
9%
Survivors
9%
Clinical Outcomes
9%
Lymphoma
9%
Hodgkin Lymphoma
9%
Caregivers
9%
Randomized Clinical Trial
9%
Proton Therapy
8%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
8%
Cancer Survivors
8%
Patient-Reported Outcomes Measurement Information System (PROMIS)
8%
Women with Breast Cancer
8%
Incidence Rate
8%
Breast
8%
Pediatric
8%
Gynecological Cancer
8%
Proton
8%
Docetaxel
8%
Testicular Germ Cell Tumor
8%
Immune Checkpoint Inhibitors
8%
Advanced Solid Tumors
8%
Patient Selection
8%
Europe
7%
Larotrectinib
7%
Targeted Therapy
7%
Median Progression-free Survival
7%
Newly Diagnosed
7%